# Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

> **NCT03459170** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Bellicum Pharmaceuticals** · enrollment: 15 (estimated)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **BIOLOGICAL:** BPX-501 T cells
- **DRUG:** rimiducid

## Key facts

- **NCT ID:** NCT03459170
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-01
- **Primary completion:** 2022-09
- **Final completion:** 2035-09
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03459170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03459170, "Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03459170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*